PMID- 24422705
OWN - NLM
STAT- MEDLINE
DCOM- 20150521
LR  - 20211203
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 14
DP  - 2014 Jan 14
TI  - Compound danshen tablet ameliorated abeta25-35-induced spatial memory impairment in 
      mice via rescuing imbalance between cytokines and neurotrophins.
PG  - 23
LID - 10.1186/1472-6882-14-23 [doi]
AB  - BACKGROUND: Compound Danshen Tablet (CDT), a Traditional Chinese Medicine, has 
      recently been reported to improve spatial cognition in a rat model of Alzheimer's 
      disease. However, in vivo neuroprotective mechanism of the CDT in models of 
      spatial memory impairment is not yet evaluated. The present study is aimed to 
      elucidate the cellular mechanism of CDT on Abeta25-35-induced cognitive impairment 
      in mice. METHODS: Mice were randomly divided into 5 groups: the control group 
      (sham operated), the Abeta25-35 treated group, the positive drug group, and large 
      and small dosage of the CDT groups, respectively. CDT was administered at a dose 
      of 0.81 g/kg and 0.405 g/kg for 3 weeks. The mice in the positive drug group were 
      treated with 0.4 mg/kg of Huperzine A, whereas the mice of the control and 
      Abeta25-35 treated groups were administrated orally with equivalent saline. After 7 
      days of preventive treatment, mice were subjected to lateral ventricle injection 
      of Abeta25-35 to establish the mice model of Alzheimer's disease. Spatial memory 
      impairment was evaluated by Morris water maze test. Choline acetyltransferase 
      (ChAT) contents in hippocampus and cortex were quantified by ELISA. The levels of 
      cytokines, receptor of activated protein kinase C1 (RACK1) and brain-derived 
      neurotrophic factor (BDNF) in hippocampus were measured by RT-PCR and ELISA. 
      RESULTS: The results showed that Abeta25-35 caused spatial memory impairment as 
      demonstrated by performance in the Morris water maze test. CDT was able to confer 
      a significant improvement in spatial memory, and protect mice from 
      Abeta25-35-induced neurotoxicity. Additionally, CDT also inhibited the increase of 
      TNF-alpha and IL-6 level, and increased the expression of choline acetyltransferase 
      (ChAT), receptor of activated protein kinase C1 (RACK1) and brain-derived 
      neurotrophic factor (BDNF) in brain as compared to model mice. CONCLUSION: These 
      findings strongly implicate that CDT may be a useful treatment against learning 
      and memory deficits in mice by rescuing imbalance between cytokines and 
      neurotrophins.
FAU - Teng, Yan
AU  - Teng Y
FAU - Zhang, Meng-Qi
AU  - Zhang MQ
FAU - Wang, Wen
AU  - Wang W
FAU - Liu, Li-Tao
AU  - Liu LT
FAU - Zhou, Li-Ming
AU  - Zhou LM
FAU - Miao, Shi-Kun
AU  - Miao SK
FAU - Wan, Li-Hong
AU  - Wan LH
AD  - Department of Pharmacology, West China School of Preclinical and Forensic 
      Medicine, Sichuan University, Chengdu, Sichuan 610041, PR China. 
      wanlihong1976@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140114
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cytokines)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-6)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuropeptides)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (RACK1 protein, mouse)
RN  - 0 (Receptors for Activated C Kinase)
RN  - 0 (Tablets)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (amyloid beta-protein (25-35))
RN  - 1693AM5SBN (dan-shen root extract)
RN  - EC 2.3.1.6 (Choline O-Acetyltransferase)
SB  - IM
MH  - Alzheimer Disease/drug therapy/metabolism
MH  - Amyloid beta-Peptides/*antagonists & inhibitors/toxicity
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - Cerebral Cortex/drug effects/enzymology/metabolism
MH  - Choline O-Acetyltransferase/metabolism
MH  - Cognition Disorders/chemically induced/drug therapy/metabolism
MH  - Cytokines/*metabolism
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/administration & dosage/*pharmacology/therapeutic use
MH  - Hippocampus/drug effects/enzymology/metabolism
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Maze Learning/drug effects
MH  - Memory Disorders/chemically induced/*drug therapy/metabolism
MH  - Mice
MH  - Nerve Growth Factors/*metabolism
MH  - Neuropeptides/metabolism
MH  - Neuroprotective Agents/administration & dosage/*pharmacology/therapeutic use
MH  - Peptide Fragments/*antagonists & inhibitors/toxicity
MH  - Receptors for Activated C Kinase
MH  - Salvia miltiorrhiza/chemistry
MH  - Spatial Memory/*drug effects
MH  - Tablets
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC3898400
EDAT- 2014/01/16 06:00
MHDA- 2015/05/23 06:00
PMCR- 2014/01/14
CRDT- 2014/01/16 06:00
PHST- 2013/07/18 00:00 [received]
PHST- 2014/01/08 00:00 [accepted]
PHST- 2014/01/16 06:00 [entrez]
PHST- 2014/01/16 06:00 [pubmed]
PHST- 2015/05/23 06:00 [medline]
PHST- 2014/01/14 00:00 [pmc-release]
AID - 1472-6882-14-23 [pii]
AID - 10.1186/1472-6882-14-23 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2014 Jan 14;14:23. doi: 10.1186/1472-6882-14-23.